Multi-center Phase II Trial of Weekly Paclitaxel Plus Cisplatin Combination Chemotherapy in Patients with Advanced Gastric and Gastro-esophageal Cancer

Sun, Qing; Liu, Chaoying; Huang, Zhong; Zhong, Bao‐Liang; Xu, Haiyuan; Shen, Wenxiang; Wang, Daoyuan

doi:10.1093/jjco/hyp008

Cited by 13 publications

(4 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Results showed that paclitaxel and its combination with paclitaxel delivered 23, 33, and 43% of response rate and 43, 23, and 40 months of 1-year survival with treatment of paclitaxel [50], paclitaxel plus carboplatin [48], and paclitaxel plus cisplatin [49], respectively. Polymeric paclitaxel micelles Genexol-PM [51] and NK105 [52] were also evaluated for efficacy and safety as Phase II trials. Results of the trials are shown in Table 13.…”

Section: Clinical Outcomes Of Polymer-paclitaxel Therapymentioning

confidence: 99%

Clinically Relevant Anticancer Polymer Paclitaxel Therapeutics

Yang

Van

2010

Cancers

View full text Add to dashboard Cite

The concept of utilizing polymers in drug delivery has been extensively explored for improving the therapeutic index of small molecule drugs. In general, polymers can be used as polymer-drug conjugates or polymeric micelles. Each unique application mandates its own chemistry and controlled release of active drugs. Each polymer exhibits its own intrinsic issues providing the advantage of flexibility. However, none have as yet been approved by the U.S. Food and Drug Administration. General aspects of polymer and nano-particle therapeutics have been reviewed. Here we focus this review on specific clinically relevant anticancer polymer paclitaxel therapeutics. We emphasize their chemistry and formulation, in vitro activity on some human cancer cell lines, plasma pharmacokinetics and tumor accumulation, in vivo efficacy, and clinical outcomes. Furthermore, we include a short review of our recent developments of a novel poly(l-γ-glutamylglutamine)-paclitaxel nano-conjugate (PGG-PTX). PGG-PTX has its own unique property of forming nano-particles. It has also been shown to possess a favorable profile of pharmacokinetics and to exhibit efficacious potency. This review might shed light on designing new and better polymer paclitaxel therapeutics for potential anticancer applications in the clinic.

show abstract

Section: Clinical Outcomes Of Polymer-paclitaxel Therapymentioning

confidence: 99%

Clinically Relevant Anticancer Polymer Paclitaxel Therapeutics

Yang

Van

2010

Cancers

View full text Add to dashboard Cite

show abstract

“… 21 Moreover, a Phase II study has shown that weekly PTX plus DDP is an active regimen with excellent tolerability for advanced gastric and gastroesophageal cancer. 22 …”

Section: Introductionmentioning

confidence: 99%

Weekly nanoparticle albumin bound-paclitaxel in combination with cisplatin versus weekly solvent-based paclitaxel plus cisplatin as first-line therapy in Chinese patients with advanced esophageal squamous cell carcinoma

Wang¹,

Yao²,

Tang³

et al. 2016

OTT

View full text Add to dashboard Cite

ObjectiveMore effective regimens for advanced esophageal squamous cell carcinoma (ESCC) are urgently needed. Therefore, a retrospective study concerning the efficacy and safety of nanoparticle albumin-bound paclitaxel plus cisplatin (nab-TP) versus solvent-based paclitaxel plus cisplatin (sb-TP) as a first-line therapy was conducted in Chinese patients with advanced ESCC.MethodsFrom June 2009 to June 2015, 32 patients were treated with nab-paclitaxel (125 mg/m2) on the first and eighth days (30 minutes infusion) and cisplatin (75 mg/m2) on the second day every 21 days (nab-TP arm). Also, 43 patients were treated with solvent-based paclitaxel (80 mg/m2) intravenously on the first and eighth days and the same dose of cisplatin (sb-TP arm). The two groups were compared in terms of objective response rate (ORR), disease control rate, progression-free survival (PFS), overall survival (OS), and safety profile. OS and PFS were estimated using Kaplan–Meier methods to determine associations between chemotherapy regimens and survival outcomes.ResultsNab-TP demonstrated a higher ORR (50% vs 30%; P=0.082) and disease control rate (81% vs 65%; P=0.124) than sb-TP. Median OS was similar for nab-TP and sb-TP (12.5 vs 10.7 months; P=0.269). However, nab-TP resulted in a longer median PFS (6.1 months [95% confidence interval: 5.3–6.9]) than sb-TP (5.0 months [95% confidence interval: 4.4–5.6]) (P=0.029). The most common adverse events included anemia, leukopenia, neutropenia, febrile neutropenia, and thrombocytopenia in both the groups and no statistically significant differences were observed between the groups. With statistically significant differences, significantly less grade ≥3 peripheral neuropathy, arthralgia, and myalgia occurred in the nab-TP arm (all P<0.05). Dose reduction, treatment delays, and second-line therapy were similar between the two regimens. There were no treatment-related deaths in either group.ConclusionNab-paclitaxel plus cisplatin is found to be an effective and tolerable option for advanced ESCC in the People’s Republic of China.

show abstract

“…With the increasing acceptance of Siewert's definition of AEG, more and more researchers have studied this clinicopathological entity 6 . However, most of the studies focused on histopathologic characteristics of AEG, surgical methods and outcomes of treatment [7][8][9][10][11] . To the best of our knowledge, there has been little investigation into the changes over time of the three subtypes of AEG.…”

Section: Introductionmentioning

confidence: 99%

Changing Pattern of Adenocarcinoma of the Esophagogastric Junction in Recent 10 Years: Experience at a Large Tertiary Medical Center in China

Wang

Yang

Duan

et al. 2012

Tumori

View full text Add to dashboard Cite

show abstract

Multi-center Phase II Trial of Weekly Paclitaxel Plus Cisplatin Combination Chemotherapy in Patients with Advanced Gastric and Gastro-esophageal Cancer

Abstract: Combination of weekly paclitaxel plus cisplatin is an active regimen with excellent tolerability as a first-line treatment of advanced gastric and gastro-esophageal cancer.

Cited by 13 publications

References 30 publications

Clinically Relevant Anticancer Polymer Paclitaxel Therapeutics

Clinically Relevant Anticancer Polymer Paclitaxel Therapeutics

Weekly nanoparticle albumin bound-paclitaxel in combination with cisplatin versus weekly solvent-based paclitaxel plus cisplatin as first-line therapy in Chinese patients with advanced esophageal squamous cell carcinoma

Changing Pattern of Adenocarcinoma of the Esophagogastric Junction in Recent 10 Years: Experience at a Large Tertiary Medical Center in China

Contact Info

Product

Resources

About